Searched for
PIRAMAL PHARMA REVENUE
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- Piramal Pharma deploying USD 85 mn capex this fiscal: Nandini PiramalPiramal Pharma is investing USD 85 million this fiscal for initiatives like capacity expansion and maintenance. They have already used USD ...
- Piramal Pharma targets to double revenue in 5 yearsPiramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The co...
- Piramal Pharma Q1 Results: Net loss narrows to Rs 89 crorePiramal Pharma Q1 Earnings: Piramal Pharma narrowed its net loss to Rs 89 crore in Q1FY25 from a net loss of Rs 99 crore in the correspondi...
- Fundamental Radar: Why does Piramal Pharma stock deserve a re-rating? Sandeep Raina explainsThe company witnessed multiple challenges related to macroeconomic factors during and after COVID-19, high attrition at European manufactur...
- After a tough year, Piramal Pharma hopes to regain vigour in 2nd halfPiramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...
- Pickup in contract manufacturing biz set to drive growth: Piramal Pharma"During the year (FY23), the customer decision-making got delayed due to macro-economic environment and pipeline prioritisation based on li...
- Piramal Pharma stock rises over 3%. Here’s whyThe brokerage firm Jefferies assigned buy rating to Piramal Pharma with a target price of Rs 150, implying an upside potential of 20% from ...
- Piramal Pharma to inject funds into expansion, acquisitionsPiramal Pharma received a $360 million investment from US private equity company Carlyle Group in October 2020 in exchange for a 20% share....
- Piramal Pharma in talks for $225 million offshore loansAt least three top lenders - Axis Bank, HSBC and State Bank of India (SBI) - are likely to extend the loan, which could be raised in the Gu...
- Piramal shares to trade ex-demerger on TuesdayPiramal Enterprises has secured the approval of the National Company Law Tribunal (NCLT) for the demerger of its pharmaceutical business an...
- Piramal Enterprise gets board nod for demerger and listing of pharma businessThe pharmaceuticals business will get vertically demerged from Piramal Enterprises and consolidated under Piramal Pharma Ltd (PPL), the gro...
- DHFL aside, pharma to drive Piramal stockThe company’s management has guided for a 15 per cent organic revenue growth in the pharma business for FY22 compared with the 1 per cent g...
- Can pharma business once again turn Ajay Piramal's fortune?The business house controls both the business segments through a listed entity Piramal Enterprises.
Load More
